

Special Issue

Acute and Post-acute Sequelae of SARS-CoV-2 Infection: Focus on Systemic Complications

Message from the Guest Editor

The coronavirus disease (COVID-19) due to a novel coronavirus (CoV2) has rapidly spread worldwide and changed various systems, especially healthcare systems. This virus not only affects the pulmonary parenchyma but also profoundly impacts the cardiovascular system. Systemic complications associated with SARS-CoV2 infection are frequently found in COVID-19 disease, with several manifestations and indiscriminate havoc on multiple organ systems including the heart, brain, kidney, and the vasculature. Moreover, long COVID-19 syndrome has emerged as a new pandemic, causing substantial disability to millions of people globally. Therefore, we would like to encourage the presentation to this Special Issue additional insights on the link between COVID-19 disease and systemic complications, in order to provide clinicians a range of the potential manifestations of SARS-CoV-2 beyond the destructive lung infection. Adding new information on these subjects may lead to a better understanding of the pathogenesis not only of COVID-19 infection but also of different diseases and aid in the design of new therapeutic and prophylactic strategies.

Guest Editor

Dr. Andrea Denegri

Cardiology Division, Parma University Hospital, via Antonio Gramsci 14,
43126 Parma, Italy

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/118276

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).